



ACCELERATING PROMISING DISCOVERIES INTO MEDICINES

Harrington Discovery Institute

 University Hospitals | Cleveland, Ohio




DELIVERING NEW TREATMENTS, MEDICINES AND CURES

Harrington Discovery Institute is an international drug discovery and development organization established to address unmet therapeutic needs across disease areas. It provides comprehensive support to leading scholars and entrepreneurs in academic centers in the US, UK, and Canada, with a focus on medical breakthroughs that show great promise but would not otherwise advance to clinical trials.

By concentrating philanthropic, scientific, and business development resources during the early, high-risk stages of development, Harrington positions therapeutic candidates for further investment and commercialization.

AREAS OF FOCUS



Major Diseases

Physician-scientist initiative including all major diseases

Brain Health Medicines

Neurodegenerative diseases, mental health, and neuromuscular disorders

Rare Diseases

Rare and ultra-rare diseases

COVID-19

Coronavirus and pandemic-causing pathogens

Harrington accelerates the development of novel treatments to address unmet medical needs through its four innovation centers.

GLOBAL NEED

1 IN 3

adults suffers from multiple chronic conditions, such as Alzheimer's, cancer, or heart disease¹

500,000

new cases of Alzheimer's disease will be diagnosed this year²


400 MILLION

people worldwide suffer from a rare disease³

3.3 MILLION

deaths from COVID-19 have been reported globally with the true death toll considered to be significantly higher⁴

OUR IMPACT



Harrington
Discovery
Institute
University Hospitals

United Kingdom

● Harrington Scholar Institutions

SUCCESS METRICS

3200+ Technology Proposals

177 Medicines in the Making

64 Institutions Supported

36 Companies Launched

19 Medicines in the Clinic

13 Licenses to Pharma

HOW WE WORK



DISCOVER: Novel discoveries are sourced from premier academic centers leveraging Harrington's transatlantic network of scientists and partner institutions.

ADVANCE: Harrington provides extensive pharma know-how through its Therapeutics Development Center. Drug development experts de-risk academic programs and help advance them into the clinical realm. Intellectual property rights remain with the Scholar/institution.

CURE: Harrington supports cures by engaging industry and investment partners able to commercialize new medicines and bring them to patients in need.

PARTNERS

Advent
Life Sciences

Alzheimer's
Drug Discovery
Foundation

BioMotiv

FOUNDATION
FIGHTING
BLINDNESS

Morgan Stanley | GIFT Cures

Nationwide®

Ohio | Third Frontier

Takeda

UNIVERSITY OF
OXFORD

University Hospitals

The Harrington
Family

Individual Philanthropic
Contributors



DISCOVER

ADVANCE

CURE

WE FIND DISCOVERIES WITH THE GREATEST POTENTIAL FOR CLINICAL IMPACT

Physicians and scientists apply for support through competitive calls for proposals. Unlike other drug discovery grants, Harrington Scholar Awards provide the grant recipient with a personalized team of drug development experts in addition to funding.

Harrington Scholars receive:

- Grant funding
- Drug development expertise
- Business development support
- Project management
- Startup support and seed investment

Proposed projects undergo a rigorous review. At each stage, the projects are evaluated by a panel of academic and industry reviewers for their **innovation, creativity, and potential for clinical impact.**



SCIENTIFIC ADVISORY BOARD

The Harrington Scientific Advisory Board (SAB) helps set the science and innovation agenda in areas of unmet need. The SAB is responsible for the selection of Harrington Scholar-Innovators, through our flagship physician-scientist program.

The Harrington SAB is comprised of medical luminaries including Nobel Prize, Lasker, Lasker-DeBakey, Pasarow, and Korsmeyer Award winners.




BREAKTHROUGH DISCOVERIES NEED TO BREAK THROUGH

At the core of Harrington Discovery Institute is a team of experienced pharma and business development professionals with a track record of bringing new drugs to market. These Therapeutics Development Center advisors work with the Scholar to bring industry standard strategies into the academic laboratory. IP rights are retained by the Scholar/Institution.



THERAPEUTICS DEVELOPMENT CENTER

De-risking and advancing discoveries into the clinic



INDUSTRY LEADERSHIP EXPERIENCE

Merck | Bristol Myers Squibb | Schering-Plough | Forest Laboratories
 GlaxoSmithKline | Johnson & Johnson | AstraZeneca | Allergan

INVESTMENT ADVISORY BOARD


The Investment Advisory Board (IAB) ensures that financial resources are directed most efficiently and effectively towards value creation.

The IAB oversees all nonprofit investments and seed-financing of start-up companies to maximize impact, thus increasing the probability of success.



CURING DISEASES IN AREAS OF UNMET NEED


Imagine a world where new treatments can be developed in months and years, not decades. Where society is healthier and people are living longer, happier lives. With the help of mission-driven partners and generous philanthropists, Harrington Discovery Institute is fueling innovative science, advancing medical breakthroughs and commercializing the next generation of medicines.



THE HARRINGTON FAMILY

“Science improves the lives of our loved ones. The opportunity to invest is a blessing; bringing medicines to those in need is a duty; and the power of this program is a gift.”

RONALD G. HARRINGTON
Philanthropist & Entrepreneur



HARRINGTON MODEL IN ACTION

A GLOBAL PARTNERSHIP TO ACCELERATE CURES FOR RARE DISEASES

The **Oxford-Harrington Rare Disease Centre**, a partnership between the University of Oxford and Harrington Discovery Institute, underpins a global initiative to develop novel treatments for rare diseases, for which therapeutic options are severely lacking.

Approximately 350 million people worldwide are living with a rare disease, and half of them are children. With more than 7,000 known rare diseases, and only five percent having an approved treatment, rare disease represents one of the greatest unmet needs in healthcare today.



OUR MISSION

is to deliver new treatments for the 350 million affected by rare diseases worldwide.

OUR VISION

is to be the global leader in eliminating rare diseases.

OUR GOAL

is to advance 20 drugs into clinical trials in the next 10 years.

A PARTNERSHIP OF



PRESS RELEASE

NEW THERAPY SEEKS TO PROTECT FROM RARE MUSCLE-WASTING DISORDER

AUGUST 2022, OXFORD, UK AND CLEVELAND, OH, USA

The Oxford-Harrington Rare Disease Centre announced its support of a novel treatment for Duchenne muscular dystrophy, a rare neuromuscular disease characterized by progressive muscle degeneration and weakness. Duchenne muscular dystrophy (DMD) primarily affects boys, usually beginning around the age of four.

CONTINUE READING: [HarringtonDiscovery.org/News](https://www.harringtondiscovery.org/News)



"I look forward to working with the Oxford-Harrington Rare Disease Centre to advance this drug candidate for utrophin replacement therapy towards clinical trials."

ANGELA RUSSELL, DPhil
University of Oxford
2021 Harrington UK Rare Disease Scholar



PARTNER WITH US

ADVANCE NEW MEDICINES

We partner with non-profit organizations, pharmaceutical companies and investors to strategically de-risk and grow diverse portfolios of discoveries. Together, we can create a customized program that meets our partner's needs while creating new treatments for the benefit of society.

Our partners are able to:

- Develop programs in areas of high unmet need
- Strengthen pharma pipelines
- Source breakthrough therapies
- Create portfolios of technologies in preparation for in-licensing or new company formation

For more information: HarringtonDiscovery.org/Partner

Harrington Discovery Institute

 University Hospitals | Cleveland, Ohio

¹ <https://pubmed.ncbi.nlm.nih.gov/30406006/#:~:text=Abstract,epidemiological%2C%20economic%20and%20patient%20burden>

² <https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures>

³ <https://globalgenes.org/>

⁴ <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality>

FOLLOW US:

